BPC-157
Synthetic pentadecapeptide · Also written BPC 157, Bepecin, PL 14736
- UK status
- Unlicensed medicine
- Availability
- Research use only
- Evidence base
- Animal studies, almost no human data
- Controlled drug
- No, but WADA prohibited
Peptide sequence, one-letter notation
GEPPPGKPADDAGLV
The short version
What it does
Sold on the promise of healing injuries faster: tendons, joints, muscles, gut. Whether it does that in people is unknown.
How it does it
The claimed mechanism is helping new blood vessels grow into damaged tissue, which would speed repair. That comes from studies in rats, not people.
The catch
Thirty years of animal research and, in a 2025 review of 544 papers, one human study. Most things that work in rats fail in people. Nobody can honestly tell you the odds either way.
Everything below goes into the detail, with sources.
BPC-157 is the compound that best illustrates the gap between what the internet says about peptides and what has actually been tested in people. There is a large body of animal research and there is almost nothing in humans.
At a glance
- Compound type
- Peptide, 15 amino acids
- Drug class
- None. No approved therapeutic class.
- Origin
- Fragment derived from a protein in human gastric juice
- Marketed for
- Tendon, ligament, muscle and gut healing
- Human trials
- Essentially none. One clinical study met inclusion in a 2025 review.
- UK status
- Unlicensed medicine. Supply for human use prohibited.
- Controlled drug
- No
- In sport
- Named under WADA S0. Prohibited at all times.
01What it is
BPC-157 is a synthetic chain of 15 amino acids, described in the literature as a stable gastric pentadecapeptide. Its sequence derives from a fragment of a protein found in human gastric juice.
It is not a GLP-1 drug and has nothing to do with weight loss. It gets grouped with them only because both fall under the word "peptide", which is the single biggest source of confusion in this whole subject.
02How it came about
BPC-157 came out of research in Zagreb from the 1990s onwards, led largely by one group, investigating a peptide fragment they associated with gastric protection and tissue repair. That group produced a substantial body of animal work over three decades.
It reached wider attention through online fitness and longevity communities rather than through clinical development. No pharmaceutical company has taken it through a full trial programme. In April 2026 the MHRA opened an investigation into UK clinics making therapeutic claims about unregulated peptides, and BPC-157 was reported as the first compound named.
03UK legal and licensing status
BPC-157 is an unlicensed medicine in the UK. It is not approved by the MHRA, the EMA or the FDA for any human use. It is not a controlled drug under the Misuse of Drugs Act, but supplying or marketing it for human use without authorisation is prohibited under the Human Medicines Regulations 2012. It cannot be lawfully prescribed.
It is sold legally as a research chemical, labelled "not for human consumption". That label is a legal position taken by the seller, not a statement about product quality, and it is the mechanism by which an unlicensed medicine reaches consumers who are not researchers.
In April 2026 the MHRA opened an investigation into UK clinics making therapeutic claims about unregulated peptides. BPC-157 was reported as the first compound named.
Athletes: WADA lists BPC-157 under S0, unapproved substances, prohibited at all times both in and out of competition. Detection methods have been published. Strict liability applies, so there is no timing strategy that makes it safe for a tested athlete.
04How it works
Proposed mechanisms come from animal work and are not settled. The most frequently cited involve effects on blood vessel formation, growth factor expression and nitric oxide signalling in damaged tissue.
Be careful with how this is presented elsewhere. A proposed mechanism from rodent studies is often described online as though it were an established action in humans. Those are different claims with very different evidence behind them.
05What it is not
Claims that attach themselves to this compound and do not hold up.
- Not a licensed medicine. Not approved by any regulator anywhere for any use.
- Not proven in humans. Over a hundred animal studies, and a 2025 systematic review of orthopaedic applications that screened 544 articles and found one clinical study.
- Not a GLP-1 or weight-loss compound. It is grouped with them only because both are called peptides.
- Not suppressed by industry. A common claim, and it confuses two different things. No trials done is not the same as trials done and hidden.
06What the evidence shows
The animal literature is genuinely substantial: over a hundred studies across three decades, reporting effects on tendon, ligament, muscle and gut healing. This is where every claim you have read originates.
The human literature is not substantial. A 2025 systematic review in the American Journal of Sports Medicine looking at orthopaedic applications screened 544 articles and found a single clinical study meeting its inclusion criteria.
Animal results do not reliably transfer to humans. Most drugs that work in rodents fail in people, which is why human trials exist. An absence of human trials is not evidence that something works and is being suppressed. It is an absence of evidence, and it means nobody, in either direction, can give you an honest figure for benefit or risk.
Long-term human safety is unknown. There is no approved label, no standardised preparation and no purity standard. Whether grey-market product matches the peptide studied in the literature is unverified in principle, not just in practice.
07Reported harms
No authoritative side effect profile exists, because that comes from regulated trials and a Summary of Product Characteristics, and neither exists here. Absence of reported harms in this situation reflects absence of systematic monitoring rather than demonstrated safety.
The documented risks are the ones that come with unregulated supply: contamination, incorrect identity, inaccurate concentration, non-sterile preparation, and no recall mechanism if something goes wrong.
08Interactions and cautions
Unknown. Interaction data comes from regulated development programmes, and there has not been one. Anyone taking it alongside prescription medicines is in genuinely uncharted territory, and their prescriber cannot advise on something with no data.
09Stopping
No withdrawal or discontinuation effects are documented, because no systematic study of use, let alone cessation, exists.
10Monitoring
Nothing is being monitored. There is no approved marker to track, no recommended checks, and no formal route to report harm, since the Yellow Card scheme covers medicines. That absence of oversight is itself the risk, distinct from anything the compound might do.
11Questions worth asking
Take these to a doctor or pharmacist. A good clinician will not mind being asked, and the answers are specific to you in a way nothing on this page can be.
- Given there is essentially no human evidence, what am I basing this decision on?
- Is there a licensed treatment for the injury or condition I am actually trying to address?
- If I compete in a tested sport, am I aware this ends my season?
12Common questions
Is BPC-157 legal in the UK?
It is an unlicensed medicine. It is not a controlled drug, but selling or supplying it for human use without MHRA authorisation is prohibited under the Human Medicines Regulations 2012. It is sold lawfully only as a research chemical, labelled not for human consumption.
Does BPC-157 work?
Nobody can honestly tell you. The animal data is extensive and reports healing effects. The human data barely exists. Most compounds that work in rodents fail in people, so animal results are a reason to run trials, not a substitute for them.
Why are there no human trials if it looks so promising?
Partly patent economics, since a compound nobody can own exclusively is hard to fund trials for. But that explains an absence of evidence, not the presence of hidden evidence. The honest position is that the unknowns are larger than the knowns.
Is it safe?
Unknown. No systematic safety monitoring exists, so an absence of reported harms reflects an absence of anyone looking. The documented risks are those of unregulated supply: unverified identity, purity, concentration and sterility.
13Sources
Links go to the authoritative source. Where a document sits behind a paywall or moves around, the full citation is given so you can find it yourself.
- Unlicensed medicines guidanceMHRA
- MHRA investigates clinics over peptide claimsAesthetics Journal, 2026
- Prohibited List, S0 unapproved substancesWADA
- BPC-157 in orthopaedics, systematic reviewAmerican Journal of Sports Medicine, 2025
- BPC 157 and its potential in healing and tissue repairCurrent Pharmaceutical Design, 2011
- BPC-157 creates risk for athletesUSADA
Get told when something changes
A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address. Unsubscribe whenever.
14Change history
Every substantive change to this record is logged here with its date. Corrections are made openly, not quietly.
Loading…
Want telling when this record changes? Follow it from your account.